Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABT-510 in Metastatic Melanoma
NCT00602199Phase 2Completed
- Sponsor
- Mayo Clinic
- Start
- Nov 2004
- Primary completion
- Jun 2005
- Modality
- Peptides, Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of abt-510 in melanoma, sponsored by Mayo Clinic. Primary endpoint: 18-week progression-free survival rate. Started Nov 2004; status: completed.
02
Drugs
abt-510
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00602199.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00602199.